MedWatch

Veloxis CEO considers label expansion and acquisitions to increase growth

Danish-American drug group Veloxis Pharmaceuticals has no research and development department, but, according to CEO Craig Collard, the company has several other opportunities to increase sales now that the main asset has started to yield profit.

Foto: Veloxis

After Veloxis for the first time reported an anticipated operating profit this year, CEO Craig Collard has started to consider the long-term growth plans.

Veloxis has no research and development department to create a successor of the company's absolute main asset, the transplant drug Envarsus. However, it does not mean that the company only lives as long as Envarsus, says Collard.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier